Does Dr. MILAN ANADKAT have financial conflicts of interest?

Dr. MILAN ANADKAT (MD) has received a total of $143,852 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $116,066 in personal promotional payouts (consulting, meals, travel) and $27,787 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MILAN ANADKAT?

According to CMS Open Payments data, Dr. MILAN ANADKAT received funding from BOEHRINGER INGELHEIM INTERNATIONAL ($35,415), ONQUALITY PHARMACEUTICALS (USA) ($27,568), and BOEHRINGER INGELHEIM PHARMACEUTICALS ($27,239).

Does Dr. MILAN ANADKAT receive research grants or speaking fees?

Dr. MILAN ANADKAT has received $116,066 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $27,787 in clinical research grants.

DR. MILAN ANADKAT

MDReal-Time Hydrated

Specialty: Dermatology

Practice Location: SAINT LOUIS, MO 63108

NPI Number: 1639267149

LIFETIME INDUSTRY VALUE

$143,852

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ANADKAT is a verified Dermatology practitioner based in SAINT LOUIS, MO.

Between 2021 and 2025, Dr. ANADKAT had an overall industry promotional and research financial footprint of $143,852 as recorded in the federal CMS Open Payments database.

$116,066 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$27,787 was allocated to sponsored clinical trials and medical research activities.

Dr. ANADKAT's primary funding source is BOEHRINGER INGELHEIM INTERNATIONAL, which accounts for $35,415 (representing 24.6% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

BOEHRINGER INGELHEIM INTERNATIONAL

Rank 1

$35,415

24.6%

ONQUALITY PHARMACEUTICALS (USA)

Rank 2

$27,568

19.2%

BOEHRINGER INGELHEIM PHARMACEUTICALS

Rank 3

$27,239

18.9%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.